<DOC>
	<DOCNO>NCT02572687</DOCNO>
	<brief_summary>The main purpose study evaluate safety ramucirumab plus MEDI4736 participant locally advance unresectable metastatic gastrointestinal thoracic malignancy include gastric gastroesophageal junction ( GEJ ) adenocarcinoma , non-small cell lung cancer ( NSCLC ) , hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Plus MEDI4736 Participants With Advanced Gastrointestinal Thoracic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Measurable metastatic disease locally advance unresectable disease Has histopathologically confirm gastric GEJ adenocarcinoma document disease progression 12 prior line systemic therapy Has histopathologically confirm nonsquamous squamous NSCLC document disease progression 13 prior line systemic therapy Has histopathologically cytologically confirm HCC , ChildPugh Class A , documented disease progression discontinuation sorafenib therapy , intolerance sorafenib therapy , αfetoprotein ( AFP ) ≥ 1.5x upper limit normal Availability tumor tissue biomarker analysis Has Eastern Cooperative Oncology Group Performance Status 0 1 Has adequate organ function Has know brain metastasis Has history prior cancer include study either treat curative intent active within past 5 year History allogeneic organ transplant Has active prior document autoimmune disease within past 24 month Has human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate illness , history immunodeficiency Has active hepatitis B hepatitis C infection , coinfection hepatitis B C virus For gastric/GEJ NSCLC participant , chronic hepatitis B hepatitis C infection . ( For HCC participant , chronic hepatitis B virus [ HBV ] infection negative HBV deoxyribonucleic acid [ DNA ] test antiviral therapy , chronic hepatitis C virus [ HCV ] infection eligible ) Has history interstitial lung disease , idiopathic pulmonary fibrosis , pneumoconiosis , noninfections pneumonitis , radiationinduced druginduced pneumonitis Has receive previous systemic therapy target program death ( PD ) 1 PDligand 1/2 signal pathway , immune checkpoint inhibitor Have receive previous systemic therapy ramucirumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>advanced</keyword>
	<keyword>immuno-oncology</keyword>
	<keyword>vascular endothelial growth factor ( VEGF )</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>PD-1</keyword>
	<keyword>PD-L1</keyword>
</DOC>